[Outcome of pregnancy with systemic lupus erythematosus treated with DNA immunoabsorbent].
OBJECTIVE
To study the outcome of pregnancy with systemic lupus erythematosus (SLE) treated by DNA immunoabsorbent therapy.


METHODS
Sixty nine SLE women with pregnancy were randomly enrolled into DNA immunoabsorbent group (35, group I) and common therapeutic group (34, group II) as control. Outcomes of pregnancy and complications were analyzed.


RESULTS
The incidence of complication and fetus loss in group I was 28.6% (10 cases) and 20.0% (7 cases), while 85.3% (29 cases) and 58.8% (20 cases) in group II, there was very significant difference respectively (P < 0.01). The incidence of premature birth was 8.6% (3 cases) in group I, 26.5% (9 cases) in group II, the difference was significant (P < 0.05).


CONCLUSIONS
DNA immunoabsorbent was more efficient than common therapy in the management of SLE with pregnancy.
Li
Guifen
G
Depatment of Obstetrics and Gynecology, Zibo First Hospital, Zibo, Shandong Province 255200, China.
Zhao
Yun
Y
Li
Yanling
Y
Wang
Aiting
A
Li
Zhijiu
Z
Lin
Enfu
E
Chen
Changzhi
C
Yu
Yaoting
Y
D000328:Adult; D004247:DNA / Q000627:therapeutic use*; D005260:Female; D005333:Fetus; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007164:Immunosorbents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D007752:Obstetric Labor, Premature / Q000517:prevention & control; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*
D007164:Immunosorbents; D004247:DNA; D006854:Hydrocortisone